The growth rate of infected deaths and the measurable mortality displacement makes that hypothesis extremely unlikely. As does (albeit in a weaker form) the te

The growth rate of infected deaths and the measurable mortality displacement makes that hypothesis extremely unlikely. As does (albeit in a weaker form) the testing of the full population of Vò. As does the testing in at least a few European countries, where the growth rate of tests outpaces that of confirmed infections. And/or where the number of tests administered vastly exceeds the number of confirmed infections. Sure, once we have anti-body tests widely available, the data will become better.